CFDE Data Portal | Search RPL34P10

	Label	Description
	RPL34P10 Gene (Entity type)	ENSG00000236489 - ribosomal protein L34 pseudogene 10
	GSE182680 GSE182683 dexamethasone 0 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228357 OGA knockdown 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115395 enzalutamide LNCaP 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE192710 ZIC2 ZNF423 inhibition stem cell 4 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE164884 nicotinamide stem cell 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Pancreas 20-29 vs 70-79 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Testis 20-29 vs 60-69 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Bladder 20-29 vs 40-49 Up Gene Set (Entity type)	A Gene Set from GTEx
	GSE252944 AKT inhibition 11 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS

RPL34P10

ENSG00000236489 - ribosomal protein L34 pseudogene 10

GSE182680 GSE182683 dexamethasone 0 v 11 human dn

A Gene Set from LINCS

GSE228357 OGA knockdown 2 v 0 human dn

A Gene Set from LINCS

GSE115395 enzalutamide LNCaP 2 v 3 human up

A Gene Set from LINCS

GSE192710 ZIC2 ZNF423 inhibition stem cell 4 v 3 human up

A Gene Set from LINCS

GSE164884 nicotinamide stem cell 2 v 3 human up

A Gene Set from LINCS

GTEx Pancreas 20-29 vs 70-79 Up

A Gene Set from GTEx

GTEx Testis 20-29 vs 60-69 Up

A Gene Set from GTEx

GTEx Bladder 20-29 vs 40-49 Up

A Gene Set from GTEx

GSE252944 AKT inhibition 11 v 13 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.